<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Am J Physiol Renal Physiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Am. J. Physiol. Renal Physiol</journal-id>
<journal-id journal-id-type="pmc">ajprenal</journal-id>
<journal-id journal-id-type="publisher-id">Am J Physiol Renal Physiol</journal-id>
<journal-id journal-id-type="publisher-id">AJPRENAL</journal-id>
<journal-title-group>
<journal-title>American Journal of Physiology - Renal Physiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1931-857X</issn>
<issn pub-type="epub">1522-1466</issn>
<publisher>
<publisher-name>American Physiological Society</publisher-name>
<publisher-loc>Bethesda, MD</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31066574</article-id>
<article-id pub-id-type="pmc">6692723</article-id>
<article-id pub-id-type="publisher-id">F-00090-2019</article-id>
<article-id pub-id-type="publisher-manuscript">F-00090-2019</article-id>
<article-id pub-id-type="doi">10.1152/ajprenal.00090.2019</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Doxorubicin induces detrusor smooth muscle impairments through myosin dysregulation, leading to a risk of lower urinary tract dysfunction</article-title>
<alt-title alt-title-type="running-head">DOXORUBICIN INDUCES DETRUSOR SMOOTH MUSCLE DYSFUNCTION</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Iguchi</surname>
<given-names>Nao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dönmez</surname>
<given-names>M. İrfan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carrasco</surname>
<given-names>Alonso</given-names>
<suffix>Jr.</suffix>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-2586-7255</contrib-id>
<name>
<surname>Wilcox</surname>
<given-names>Duncan T.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pineda</surname>
<given-names>Ricardo H.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Malykhina</surname>
<given-names>Anna P.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cost</surname>
<given-names>Nicholas G.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<aff id="aff1"><sup>1</sup>Division of Urology, Department of Surgery, <institution>University of Colorado Denver School of Medicine</institution>, <addr-line>Aurora, Colorado</addr-line></aff>
<aff id="aff2"><sup>2</sup><institution>Children’s Hospital Colorado</institution>, <addr-line>Aurora, Colorado</addr-line></aff>
<aff id="aff3"><sup>3</sup>Children’s Mercy Kansas City, <addr-line>Kansas City, Missouri</addr-line></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Address for reprint requests and other correspondence: N. G. Cost, Children’s Hospital Colorado, 13123 E. 16th Ave., Aurora, CO 80045 (e-mail: <email>nicholas.cost@childrenscolorado.org</email>).</corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>1</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>8</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>7</month>
<year>2020</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>317</volume>
<issue>1</issue>
<fpage>F197</fpage>
<lpage>F206</lpage>
<history>
<date date-type="received">
<day>26</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>10</day>
<month>4</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>3</day>
<month>5</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 the American Physiological Society</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>American Physiological Society</copyright-holder>
</permissions>
<self-uri content-type="pdf" xlink:href="ajprenal.00090.2019.pdf"></self-uri>
<abstract>
<p>Cytotoxic chemotherapy is the foundation for the treatment of the wide variety of childhood malignancies; however, these therapies are known to have a variety of deleterious side effects. One common chemotherapy used in children, doxorubicin (DOX), is well known to cause cardiotoxicity and cardiomyopathy. Recent studies have revealed that DOX impairs skeletal and smooth muscle function and contributes to fatigue and abnormal intestinal motility in patients. In this study, we tested the hypothesis that systemic DOX administration also affects detrusor smooth muscle (DSM) function in the urinary bladder, especially when administered at a young age. The effects on the DSM and bladder function were assessed in BALB/cJ mice that received six weekly intravenous injections of DOX (3 mg·kg<sup>−1</sup>·wk<sup>−1</sup>) or saline for the control group. Systemic DOX administration resulted in DSM hypertrophy, increased voiding frequency, and a significant attenuation of DSM contractility, followed by a slower relaxation compared with the control group. Gene expression analyses revealed that unlike DOX-induced cardiotoxicity, the bladders from DOX-administered animals showed no changes in oxidative stress markers; instead, downregulation of large-conductance Ca<sup>2+</sup>-activated K<sup>+</sup> channels and altered expression of myosin light-chain kinase coincided with reduced myosin light-chain phosphorylation. These results indicate that in vivo DOX exposure caused DSM dysfunction by dysregulation of molecules involved in the detrusor contractile-relaxation mechanisms. Collectively, our findings suggest that survivors of childhood cancer treated with DOX may be at increased risk of bladder dysfunction and benefit from followup surveillance of bladder function.</p>
</abstract>
<kwd-group>
<kwd>bladder dysfunction</kwd>
<x xml:space="preserve">; </x>
<kwd>detrusor</kwd>
<x xml:space="preserve">; </x>
<kwd>doxorubicin</kwd>
<x xml:space="preserve">; </x>
<kwd>myosin</kwd>
<x xml:space="preserve">; </x>
<kwd>smooth muscle</kwd>
</kwd-group>
<funding-group>
<award-group id="award1">
<funding-source>
<named-content content-type="funder-name">Colorado Clinical and Translational Science Institute</named-content>
</funding-source>
<award-id>KL2 TR001080</award-id>
</award-group>
<award-group id="award2">
<funding-source>
<named-content content-type="funder-name">Ponzio family Endowment Fund</named-content>
</funding-source>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>